在接受门手术的患者中,轻度功能障碍的预后影响
Kitae Kim1, Taeksu Kim1, Sungsil Yoon1
1Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
概括
轻微的功能障碍不会显著影响心脏门手术患者的预后. 虽然整体功能障碍会影响结果,但轻度功能障碍与术后结果有非线性关联.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 外科手术的结果
背景情况:
- 功能障碍是心脏手术中不良结果的已知危险因素.
- 轻度功能障碍对门手术后预后的具体影响需要进一步澄清.
研究的目的:
- 在接受心脏门手术的患者中分析轻度功能障碍的预后影响.
- 调查估计的膜过率与临床结果之间的非线性关联.
主要方法:
- 分析了一组6210名接受左侧心脏门手术的患者.
- 限制立方脊柱功能和治疗权重的逆概率被用来评估估计的淋巴膜过率和结果 (全因死亡,综合死亡,重新手术,中风,心力衰竭) 之间的关联.
主要成果:
- 临床结果与功能障碍的程度有显著差异.
- 轻度功能障碍 (57.3%的患者) 没有显示出对全因死亡率或综合结局的显著不良影响.
- 观察到一种非线性关联,低估计的膜过率在轻度功能障碍下降的不良影响.
结论:
- 基线功能障碍的程度,而不仅仅是轻微的功能障碍,与门手术患者的长期临床结果有显著联系.
- 基线功能和术后结果之间存在非线性关系.
相关概念视频
Mitral Regurgitation III: Medical Management
4
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
4
Factors Affecting Renal Clearance: Renal Impairment
54
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
54
Mitral Regurgitation IV: Nursing Management
3
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
3
Mitral Stenosis I: Introduction
2
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
2
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386


